Healthcare Industry News: joint replacement
News Release - March 27, 2006
TissueLink Medical Announces Presentation of New Clinical Data Documenting Reduction in Blood Loss with the Company's Bipolar Sealing TechnologyFindings Presented at the American Academy of Orthopaedic Surgeons 2006 Annual Meeting
DOVER, N.H.--(HSMN NewsFeed)--March 27, 2006--TissueLink Medical, Inc., a privately held medical device company, announced today that clinical data from two separate studies involving the Company's innovative bipolar sealing technology was presented during the 2006 Annual Meeting of the American Academy of Orthopedic Surgeons held in Chicago, Illinois. The data presented documented that the use of TissueLink's saline-enhanced radiofrequency technology was associated with significant reductions in blood loss in patients undergoing total joint replacement procedures.
Researchers from the Rubin Institute for Advanced Orthopaedics at Sinai Hospital of Baltimore presented data from a randomized, prospective study demonstrating that the use of TissueLink's technology was associated with a significant reduction in intra-operative and post-operative blood loss and a significant reduction in the need for blood transfusions in patients undergoing total hip replacement surgery.
"Blood conservation and avoiding transfusions remain major concerns for both patients and their surgeons in total hip arthroplasty," stated Michael A. Mont, M.D., Director of the Center for Joint Preservation and Reconstruction at Sinai Hospital of Baltimore and principal investigator for the study. "The results of our study show that the use of TissueLink's bipolar sealer device during total hip replacement procedures effectively controls intra- and post-operative blood loss and may reduce blood-related risks by helping to diminish the need for blood product transfusions."
Results from a separate randomized, prospective study reporting clinical data associated with the use of TissueLink's bipolar sealing technology in patients undergoing total knee replacement surgery were presented by researchers from St. Vincent Hospital in Indianapolis, Indiana. The authors reported that the use of TissueLink's technology was associated with a significant reduction in blood loss, as measured by hemoglobin loss, compared to patients managed via a conventional approach.
"Undergoing total knee replacement exposes patients to the potential for major perioperative blood loss," stated Philip H. Ireland, M.D., an orthopaedic surgeon from St. Vincent's Hospital in Carmel, Indiana and co-investigator for the study. "Minimizing blood loss with TissueLink's bipolar sealing technology may reduce the risk of transfusions and improves patient outcomes following surgery."
"We were extremely pleased with the positive clinical results from both of these well controlled clinical trials," said Jacqueline Eastwood, TissueLink's President and Chief Executive Officer. "These results continue to validate TissueLink's technology as an effective tool which can assist surgeons to reduce surgical blood loss and its associated intra- and post-operative complications while also helping to improve patient outcomes."
About TissueLink Medical:
TissueLink Medical, Inc., develops and markets innovative products that simplify surgery and improve patient outcomes. The company's patented saline-enhanced radiofrequency platform technology is designed to reduce or eliminate bleeding during a wide variety of surgical procedures.
For more information on TissueLink Medical, visit the company website at www.tissuelink.com.
Source: TissueLink Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.